These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16220987)

  • 1. Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
    Becker DP; Villamil CI; Barta TE; Bedell LJ; Boehm TL; Decrescenzo GA; Freskos JN; Getman DP; Hockerman S; Heintz R; Howard SC; Li MH; McDonald JJ; Carron CP; Funckes-Shippy CL; Mehta PP; Munie GE; Swearingen CA
    J Med Chem; 2005 Oct; 48(21):6713-30. PubMed ID: 16220987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.
    Becker DP; Barta TE; Bedell LJ; Boehm TL; Bond BR; Carroll J; Carron CP; Decrescenzo GA; Easton AM; Freskos JN; Funckes-Shippy CL; Heron M; Hockerman S; Howard CP; Kiefer JR; Li MH; Mathis KJ; McDonald JJ; Mehta PP; Munie GE; Sunyer T; Swearingen CA; Villamil CI; Welsch D; Williams JM; Yu Y; Yao J
    J Med Chem; 2010 Sep; 53(18):6653-80. PubMed ID: 20726512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
    Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
    Venkatesan AM; Davis JM; Grosu GT; Baker J; Zask A; Levin JI; Ellingboe J; Skotnicki JS; Dijoseph JF; Sung A; Jin G; Xu W; McCarthy DJ; Barone D
    J Med Chem; 2004 Dec; 47(25):6255-69. PubMed ID: 15566296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Davis JM; Grosu GT; Baker J; Ellingboe J; Zask A; Levin JI; Sandanayaka VP; Du M; Skotnicki JS; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R; Tillett J; Zhao W; McDevitt J; Xu ZB
    J Med Chem; 2003 Jun; 46(12):2376-96. PubMed ID: 12773042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.
    Kolodziej SA; Hockerman SL; Boehm TL; Carroll JN; DeCrescenzo GA; McDonald JJ; Mischke DA; Munie GE; Fletcher TR; Rico JG; Stehle NW; Swearingen C; Becker DP
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3557-60. PubMed ID: 20529684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
    Scozzafava A; Supuran CT
    J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.
    Kolodziej SA; Hockerman SL; DeCrescenzo GA; McDonald JJ; Mischke DA; Munie GE; Fletcher TR; Stehle N; Swearingen C; Becker DP
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3561-4. PubMed ID: 20529685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
    Barta TE; Becker DP; Bedell LJ; Easton AM; Hockerman SL; Kiefer J; Munie GE; Mathis KJ; Li MH; Rico JG; Villamil CI; Williams JM
    Bioorg Med Chem Lett; 2011 May; 21(10):2820-2. PubMed ID: 21507637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
    Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
    J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.
    Park K; Aplasca A; Du MT; Sun L; Zhu Y; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3927-31. PubMed ID: 16723229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carborane-Containing Matrix Metalloprotease (MMP) Ligands as Candidates for Boron Neutron-Capture Therapy (BNCT).
    Lutz MR; Flieger S; Colorina A; Wozny J; Hosmane NS; Becker DP
    ChemMedChem; 2020 Oct; 15(20):1897-1908. PubMed ID: 32720425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
    Wada CK; Holms JH; Curtin ML; Dai Y; Florjancic AS; Garland RB; Guo Y; Heyman HR; Stacey JR; Steinman DH; Albert DH; Bouska JJ; Elmore IN; Goodfellow CL; Marcotte PA; Tapang P; Morgan DW; Michaelides MR; Davidsen SK
    J Med Chem; 2002 Jan; 45(1):219-32. PubMed ID: 11754593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMP-2 selectivity in hydroxamate-type inhibitors.
    Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B
    Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and screening of N-alkyl hydroxamates for inhibition of cancer cell proliferation.
    Stanger KJ; Sliva D; Jiang J; Krchnák V
    Comb Chem High Throughput Screen; 2006 Nov; 9(9):651-61. PubMed ID: 17100571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
    Becker DP; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Munie GE; Swearingen C
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2723-5. PubMed ID: 11591510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid-phase synthesis of an arylsulfone hydroxamate library.
    Salvino JM; Mathew R; Kiesow T; Narensingh R; Mason HJ; Dodd A; Groneberg R; Burns CJ; McGeehan G; Kline J; Orton E; Tang SY; Morrisette M; Labaudininiere R
    Bioorg Med Chem Lett; 2000 Aug; 10(15):1637-40. PubMed ID: 10937713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities.
    Yang F; Han L; Zhao N; Yang Y; Ge D; Zhang H; Chen Y
    Future Med Chem; 2020 Apr; 12(8):655-672. PubMed ID: 32202140
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
    Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.